E Selzer

Summary

Affiliation: University of Vienna
Country: Austria

Publications

  1. ncbi Erythropoietin receptor expression in human melanoma cells
    E Selzer
    Department of Radiotherapy and Radiobiology, University Hospital, Vienna, Austria
    Melanoma Res 10:421-6. 2000
  2. ncbi Effects of betulinic acid alone and in combination with irradiation in human melanoma cells
    E Selzer
    Department of Radiotherapy and Radiobiology, University Hospital, Vienna, Austria
    J Invest Dermatol 114:935-40. 2000
  3. ncbi Protein kinase C isoforms in normal and transformed cells of the melanocytic lineage
    E Selzer
    Department of Radiotherapy and Radiobiology, University Hospital Vienna, Vienna, Austria
    Melanoma Res 12:201-9. 2002
  4. ncbi Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx
    C M Glaser
    University Clinics for Oral and Maxillofacial Surgery, General Hospital, Vienna, Austria
    Int J Radiat Oncol Biol Phys 50:705-15. 2001
  5. doi Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial
    L Vormittag
    Division of Clinical Oncology, Department of Medicine I and Cancer Center, Medical University Vienna, Vienna, Austria
    Strahlenther Onkol 188:235-42. 2012
  6. doi Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound
    M Willmann
    Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria
    Eur J Clin Invest 39:384-94. 2009
  7. doi HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer
    C Perisanidis
    Departments of Cranio, Maxillofacial and Oral Surgery, Medical University of Vienna, Vienna, Austria
    Oral Dis 19:206-11. 2013
  8. ncbi Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    D Thurnher
    Department of Otorhinolaryngology, Division of Oncology, University Hospital of Vienna, Vienna, Austria
    Anticancer Drugs 12:205-8. 2001

Collaborators

Detail Information

Publications8

  1. ncbi Erythropoietin receptor expression in human melanoma cells
    E Selzer
    Department of Radiotherapy and Radiobiology, University Hospital, Vienna, Austria
    Melanoma Res 10:421-6. 2000
    ..This observation might be useful in the early diagnosis of melanoma...
  2. ncbi Effects of betulinic acid alone and in combination with irradiation in human melanoma cells
    E Selzer
    Department of Radiotherapy and Radiobiology, University Hospital, Vienna, Austria
    J Invest Dermatol 114:935-40. 2000
    ....
  3. ncbi Protein kinase C isoforms in normal and transformed cells of the melanocytic lineage
    E Selzer
    Department of Radiotherapy and Radiobiology, University Hospital Vienna, Vienna, Austria
    Melanoma Res 12:201-9. 2002
    ....
  4. ncbi Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx
    C M Glaser
    University Clinics for Oral and Maxillofacial Surgery, General Hospital, Vienna, Austria
    Int J Radiat Oncol Biol Phys 50:705-15. 2001
    ....
  5. doi Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial
    L Vormittag
    Division of Clinical Oncology, Department of Medicine I and Cancer Center, Medical University Vienna, Vienna, Austria
    Strahlenther Onkol 188:235-42. 2012
    ....
  6. doi Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound
    M Willmann
    Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria
    Eur J Clin Invest 39:384-94. 2009
    ..We here present a novel semi-synthetic betulinic acid-derived drug candidate well suited for further clinical development...
  7. doi HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer
    C Perisanidis
    Departments of Cranio, Maxillofacial and Oral Surgery, Medical University of Vienna, Vienna, Austria
    Oral Dis 19:206-11. 2013
    ..In this study, we assessed the prognostic significance of HCRP1 expression in patients with oral and oropharyngeal squamous cell carcinoma (OOSCC)...
  8. ncbi Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    D Thurnher
    Department of Otorhinolaryngology, Division of Oncology, University Hospital of Vienna, Vienna, Austria
    Anticancer Drugs 12:205-8. 2001
    ..Severe organ toxicity except alopecia (91%) was not observed. Ifosfamide combined with mitoxantrone does not improve the therapeutic armentarium in recurrent squamous cell carcinoma of the head and neck...